Integral Health Asset Management LLC Purchases 200,000 Shares of Revolution Medicines, Inc. (NASDAQ:RVMD)

Integral Health Asset Management LLC boosted its position in Revolution Medicines, Inc. (NASDAQ:RVMD) by 57.1% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 550,000 shares of the company’s stock after buying an additional 200,000 shares during the period. Revolution Medicines makes up 2.1% of Integral Health Asset Management LLC’s holdings, making the stock its 10th biggest holding. Integral Health Asset Management LLC owned about 0.33% of Revolution Medicines worth $24,057,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also bought and sold shares of RVMD. CIBC Asset Management Inc boosted its holdings in Revolution Medicines by 5.7% during the fourth quarter. CIBC Asset Management Inc now owns 5,037 shares of the company’s stock worth $220,000 after purchasing an additional 270 shares during the last quarter. Russell Investments Group Ltd. boosted its holdings in Revolution Medicines by 11.4% during the fourth quarter. Russell Investments Group Ltd. now owns 4,243 shares of the company’s stock worth $186,000 after purchasing an additional 434 shares during the last quarter. Amalgamated Bank boosted its holdings in Revolution Medicines by 8.3% during the fourth quarter. Amalgamated Bank now owns 5,707 shares of the company’s stock worth $250,000 after purchasing an additional 435 shares during the last quarter. CANADA LIFE ASSURANCE Co boosted its holdings in Revolution Medicines by 5.0% during the fourth quarter. CANADA LIFE ASSURANCE Co now owns 11,398 shares of the company’s stock worth $498,000 after purchasing an additional 545 shares during the last quarter. Finally, Arizona State Retirement System boosted its holdings in Revolution Medicines by 2.0% during the fourth quarter. Arizona State Retirement System now owns 33,905 shares of the company’s stock worth $1,483,000 after purchasing an additional 650 shares during the last quarter. Institutional investors and hedge funds own 94.34% of the company’s stock.

Revolution Medicines Trading Down 3.2%

Shares of NASDAQ RVMD opened at $40.58 on Monday. The firm has a 50 day moving average of $37.36 and a 200 day moving average of $43.39. The firm has a market capitalization of $7.56 billion, a price-to-earnings ratio of -11.30 and a beta of 1.11. Revolution Medicines, Inc. has a 12-month low of $29.17 and a 12-month high of $62.40.

Revolution Medicines (NASDAQ:RVMD) last announced its earnings results on Wednesday, May 7th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same quarter in the prior year, the company posted ($0.70) EPS. Sell-side analysts predict that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Insider Buying and Selling

In related news, CFO Jack Anders sold 1,864 shares of the company’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $72,770.56. Following the sale, the chief financial officer now owns 115,006 shares of the company’s stock, valued at $4,489,834.24. This represents a 1.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider Mark A. Goldsmith sold 11,738 shares of the business’s stock in a transaction on Monday, March 17th. The shares were sold at an average price of $39.04, for a total transaction of $458,251.52. Following the transaction, the insider now owns 441,564 shares in the company, valued at $17,238,658.56. This trade represents a 2.59% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 16,660 shares of company stock worth $650,406. 8.00% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

RVMD has been the topic of a number of research analyst reports. Guggenheim dropped their target price on shares of Revolution Medicines from $87.00 to $80.00 and set a “buy” rating on the stock in a research note on Thursday. HC Wainwright boosted their target price on shares of Revolution Medicines from $72.00 to $73.00 and gave the company a “buy” rating in a research note on Monday, March 3rd. Oppenheimer boosted their target price on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an “outperform” rating in a research note on Thursday. Stifel Nicolaus dropped their target price on shares of Revolution Medicines from $78.00 to $64.00 and set a “buy” rating on the stock in a research note on Tuesday, April 1st. Finally, Wedbush reiterated an “outperform” rating and issued a $67.00 target price on shares of Revolution Medicines in a research note on Thursday. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has an average rating of “Buy” and a consensus price target of $67.17.

Revolution Medicines Company Profile

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company’s research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.